エピソード

  • Can We Delay Alzheimer's Symptoms Before They Begin? Inside the PrevenTRON Trial

    Can We Delay Alzheimer's Symptoms Before They Begin? Inside the PrevenTRON Trial
    2026/09/04
    Episode description: Dr. Geoff Kerchner, Vice President and Global Head of Neurodegeneration at Roche, Basel, Switzerland, discusses the science behind PrevenTRON, a prevention study evaluating trontinemab in individuals with preclinical Alzheimer disease. Keywords: trontinemab, Alzheimer's, Alzheimer disease, dementia, mild cognitive impairment, MCI, amyloid-targeting therapies, Roche, PrevenTRON, TRONTIER, brain health, cognitive health
    続きを読む 一部表示
    9 分
  • Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection

    Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection
    2026/08/19
    Dr. Michael Irizarry, Senior Vice-President, Clinical Research, Eisai, Nutley, NJ, discusses the evidence supporting subcutaneous lecanemab for early Alzheimer disease, including dosing, amyloid clearance, and safety monitoring.
    続きを読む 一部表示
    12 分
  • Next-Generation CNS Drug Delivery: Brainshuttle Technology and Clinical Implications in Alzheimer Disease

    Next-Generation CNS Drug Delivery: Brainshuttle Technology and Clinical Implications in Alzheimer Disease
    2026/07/17
    In this episode, Luka Kulic, MD, Vice President and Global Head of Early Clinical Development in Neuroscience and Rare Diseases at Roche, Basel, Switzerland, discusses the investigational Brainshuttle technology, including results from the BrainShuttle AD clinical trials as a treatment for early Alzheimer disease along with the broader implications of enhanced blood-brain barrier drug delivery in neurology.
    続きを読む 一部表示
    15 分
  • Advancing MOGAD Care

    Advancing MOGAD Care
    2026/06/23
    Episode Description: What do the latest METEOROID trial results mean for neurologists treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)? Michael Levy, MD, Massachusetts General Hospital, Boston, MA, discusses relapse prevention, diagnostic challenges, and the future of MOGAD management with Peter Sguigna, MD, UT Southwestern Medical Center, Dallas, TX.
    続きを読む 一部表示
    10 分
  • Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances

    Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances
    2026/05/15
    Richard J. Nowak, MD, MS, Associate Professor of Neurology, Yale School of Medicine, Yale University, New Haven, CT and global principal investigator of the Myasthenia Gravis Inebilizumab Trial (MINT), discusses the phase 3 results, highlighting the safety and efficacy of CD19-targeted B-cell therapy for individuals with generalized myasthenia gravis and its impact on outcomes and steroid reduction in real-world practice. Additional details about MINT may be found in the following publication: The New England Journal of Medicine. For more information on the medication discussed in this episode, please refer to the Full Prescribing Information provided by Amgen, last updated 12/2025.
    続きを読む 一部表示
    16 分
  • The Use of Intracranial Vessel Wall MRI for the Diagnosis of Vasculitis

    The Use of Intracranial Vessel Wall MRI for the Diagnosis of Vasculitis
    2025/10/29
    Jae W. Song, MD, MS, Associate Professor of Radiology at the University of Pennsylvania, Philadelphia, PA, discusses the diagnostic value of intracranial vessel wall MRI for vasculitis, as well as when clinicians should order this imaging technique and the challenges that may arise.
    続きを読む 一部表示
    8 分
  • Ocrevus Treatment in Pregnant and Lactating Women with Multiple Sclerosis

    Ocrevus Treatment in Pregnant and Lactating Women with Multiple Sclerosis
    2025/10/29
    Riley Bove, MD, UCSF School of Medicine, San Francisco, CA details results from the MINORE and SOPRANINO studies examining Ocrevus treatment in pregnant and lactating women with multiple sclerosis.
    続きを読む 一部表示
    14 分
  • New Guidelines for the Assessment of Traumatic Brain Injury

    New Guidelines for the Assessment of Traumatic Brain Injury
    2025/05/07
    Beth McQuiston, MD, RD, Medical Director, Abbott, Abbott Park, IL, and David Okonkwo, MD, PhD, Professor of Neurological Surgery, University of Pittsburgh, Pittsburg, PA, describe some of the important updates to guidelines for the assessment of traumatic brain injury, including biomarker testing.
    続きを読む 一部表示
    21 分